Blog · Tech & news
Continuous glucose and ketone monitoring, explained
Most of us who live with type 1 diabetes already speak fluent CGM. Trend arrows. Alerts. The quiet relief of catching a slide before it becomes a scavenger hunt for juice.
Ketones have usually lived in a different lane: a strip, a meter, a fingerstick culture of “check when you feel off, when you are ill, or when your care team says so.” That split is starting to close. In August 2026, the U.S. FDA authorized Abbott’s Libre Duo 10 Day system, described as the first U.S. wearable to continuously monitor ketones and the first worldwide to continuously monitor both ketones and glucose in one device.
This post is orientation, not a shopping brief and not a treatment plan. Availability, coverage, and whether a device fits your regimen are clinic conversations.
What the authorization actually said
According to the FDA’s August 25, 2026 announcement, Libre Duo 10 Day is authorized for people aged 2 years and older with diabetes. The agency frames it as continuous ketone monitoring alongside glucose, with readings updating frequently to a compatible smartphone and alert capability for concerning ketone thresholds. Authorization used the De Novo pathway after Breakthrough Device designation, with clinical and performance data across multiple studies.
Abbott’s own August 25, 2026 media release says the company plans a U.S. launch later in 2026, and positions the system for people at higher risk of elevated ketones, including those using insulin or certain glucose-lowering agents such as SGLT2 inhibitors. Company materials also discuss future compatibility with selected automated insulin delivery systems over time. Treat launch timelines and integrations as company statements until your clinician and insurer confirm what is actually available to you.
Why ketones matter next to glucose
Glucose answers “where is the sugar right now and where is it headed?” Ketones answer a different question: is the body producing ketone bodies in a way that can signal risk for diabetic ketoacidosis (DKA), especially when you are ill, missing insulin, or in other high-risk situations your team has already flagged for you.
One educational reason continuous ketone data gets attention: DKA risk is not always mirrored by a dramatic high on the CGM. Some medication contexts and illness patterns can look “not that high” on glucose while ketones still rise. That is exactly why your care team’s sick-day and ketone rules matter more than any single product headline.
What this is not
- Not a reason to change insulin, pump settings, or sick-day plans from a blog
- Not a guarantee of insurance coverage or local pharmacy stock
- Not a replacement for emergency care if you have symptoms of DKA
- Not medical advice tailored to your history, meds, or devices
Questions worth bringing to clinic
If you are curious about dual glucose-ketone monitoring, useful clinic questions sound like logistics and fit, not hype:
- For my risk profile, when do you want ketone information, and how do you want me to act on it?
- How does continuous ketone data interact with my current CGM, pump, or AID system?
- What coverage or prior-auth path should I expect if this becomes available?
- What symptoms or ketone thresholds still mean “go to urgent or emergency care,” regardless of the wearable?
How this fits The Diabetic Dose
We are building a knowledge hub: practical day-to-day systems, plain-language education, and sourced news. Travel kits and overnight highs still matter. So do device categories and regulatory milestones that change what patients and clinicians can even discuss.
For the short news card version of this story, see our Diabetes News roundup and What’s New. For the lived packing side of backups and illness readiness, the free checklist is still the grab-and-go companion.
More tech context: Hardware · Software · What’s New
Follow day-to-day T1D logistics: Instagram @thediabeticdose